NM_001382430.1:c.49_51delGAGinsCAA

Variant names:

• chr14-104780212-CTC-TTG
• NM_001382430.1:c.49_51delGAGinsCAA
• AKT1 p.Glu17Gln

GermlineCancer (beta)

Variant summary

Our verdict is Uncertain significance.

+5 Uncertain · Hot

-7

-6

-1

0

+5

+6

+9

+10

BenignB

Likely BenignLB

UncertainVUS

Likely PathogenicLP

PathogenicP

The variant received 5 classification points (ACGS-UK Somatic Oncogenicity v2025). O3_ModerateO5_SupportingO6_SupportingO7_Supporting

The NM_001382430.1(AKT1):c.49_51delGAGinsCAA (p.Glu17Gln) variant causes a missense, splice region change. The gene AKT1 is a known oncogene (CancerMine: 20 TSG, 294 oncogene, 149 driver citations). The gene AKT1 is a cancer driver gene (CancerMine: 20 TSG, 294 oncogene, 149 driver citations). Note: allele frequency estimates from gnomAD may be inaccurate for this variant type (MNP or indel longer than 3 bp) due to technology limitations. The variant is absent from the gnomAD population database at sites with sufficient sequencing coverage. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.92). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.E17R: Pathogenic (ClinVar VariationId 800567, 1 star) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.E17?: Uncertain_significance (ClinVar VariationId 1524334, 1 star) A different missense variant at the same amino acid position has been reported as oncogenic in ClinVar. The variant position is a cancer hotspot (cancerhotspots.org) with 298 samples affected at this amino acid position.

• Frequency: Genomes: not found (cov: 33)
• Consequence: AKT1 NM_001382430.1 missense, splice_region
• Clinical Significance: Not reported in ClinVar
• Conservation: PhyloP100: 7.92
• Publications: 0 publications found

Genes affected

AKT1 (HGNC:391): (AKT serine/threonine kinase 1) This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]

AKT1 Gene-Disease associations (from GenCC):

• Proteus syndrome

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), PanelApp Australia, G2P
• Cowden disease

  Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
• Cowden syndrome 6

  Inheritance: AD, Unknown Classification: LIMITED Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), ClinGen

Classification according to ACGS-UK Somatic Oncogenicity v2025

Classification was made for transcript:

Our verdict: Uncertain_significance. The variant received 5 points.

Apply	Criterion Code & Title / Strength	Strength	Rationale / Clinical Context
	O3Absent or very rare in population		Absent or extremely rare in gnomAD (AC ≤ 2) — O3 moderate; GnomAD: AF = absent, AC = 0 — absent/extremely rare (O3 moderate [+2])
	O5Same location/impact as known oncogenic		Different AA at same residue with oncogenic evidence (or germline P/LP in TSG), or same AA change SCI Tier II Potential — Supporting (O5); Beware: this change may impact splicing rather than at the amino acid/protein level; ClinVar same-AA oncogenic/T1: false | ClinVar same-AA SCI tier: — | CGI same-AA oncogenic: false | TSG: false | ClinVar same-AA germline P/LP: false | CIViC LOF: false | ClinVar diff-AA oncogenic: true | ClinVar diff-AA germline P/LP: true
	O6Computational evidence supports deleterious effect		Computational evidence supports a deleterious/oncogenic effect; Missense variant — primary computational scorer does not indicate an oncogenic effect; O6 not met via missense path; Splice-region variant — splicing algorithms predict an impact on splicing; supports O6
	O7Mutational hotspot or critical domain		Supporting: cancerhotspots.org hit, critical domain, or missense neighbourhood hotspot; Note: exclude MSK/TCGA-derived samples from cancerhotspots count to avoid double-counting with O4; cancerhotspots.org: total samples at AA position = 298, same AA change = 0; Exclude MSK/TCGA-derived samples from count to avoid double-counting with O4; UniProt domain: 0 pathogenic, 0 benign.; ±8 AA neighbourhood: 1 pathogenic, 0 benign (OR vs. background: 15.0); No cancerhotspots.org splice hotspot hit at this position

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_001382430.1. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

Sel.	Gene / Transcript	Tags	HGVSc / HGVSp	Effect	Exon rank	Protein / UniProt
	AKT1 NM_001382430.1	MANE Select	c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: NP_001369359.1 UniProt:
	AKT1 NM_001014431.2		c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: NP_001014431.1 UniProt:
	AKT1 NM_001014432.2		c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: NP_001014432.1 UniProt:

AKT1 NM_001382430.1

MANE Select

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: NP_001369359.1UniProt: P31749-1B0LPE5

AKT1 NM_001014431.2

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: NP_001014431.1UniProt: B0LPE5P31749-1

AKT1 NM_001014432.2

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: NP_001014432.1UniProt: P31749-1B0LPE5

Ensembl Transcripts

Sel.	Gene / Transcript	Tags	HGVSc / HGVSp	Effect	Exon rank	Protein / UniProt
	AKT1 ENST00000649815.2	MANE Select	c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: ENSP00000497822.1 UniProt:
	AKT1 ENST00000349310.7	TSL:1	c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: ENSP00000270202.4 UniProt:
	AKT1 ENST00000402615.6	TSL:1	c.49_51delGAGinsCAA p.Glu17Gln	missensesplice_region	N/A	Prot: ENSP00000385326.2 UniProt:

AKT1 ENST00000649815.2

MANE Select

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: ENSP00000497822.1UniProt: P31749-1

AKT1 ENST00000349310.7

TSL:1

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: ENSP00000270202.4UniProt: P31749-1

AKT1 ENST00000402615.6

TSL:1

HGVSc / HGVSpc.49_51delGAGinsCAAp.Glu17Gln

Exon rankN/A

missensesplice_region

Prot: ENSP00000385326.2UniProt: P31749-1

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)

Rare (AF ≤ 0.0001 / Hom ≤ 1)

Source / population	AF	AC	Hom	AN	Coverage
Global population databases 2 sources Large-scale international reference populations
GnomAD3 genomes	AF:	AC:	Hom:	AN:	Cov:33
GnomAD4 genome	AF:	AC:	Hom:	AN:	Cov:33

Showing 2 sources

Tested, but no data found:GnomAD4 exomeIf GnomAD4 is missing, the position is probably not covered by the project.

ClinVar

Not reported in ClinVar

Computational Scores

Algorithm	Calibrated pred.	Score	Prediction
PhyloP100	Pathogenic	7.9

Showing 1 of 1 scores

Splicing Scores

No splicing scores have been computed for this variant.

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Other links and lift over

hg19: chr14-105246549;

ACMG debug oncogenicity

ACGS debug oncogenicity

ACMG debug germline

Submit to ClinVar